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Measuring Illness Representations in Breast Cancer Survivors (BCS) prescribed 
tamoxifen:  Modification and validation of the Revised Illness Perceptions 
Questionnaire (IPQ-BCS)  
Abstract 
Objective: The Revised Illness Perceptions Questionnaire (IPQ-R), widely used to assess 
illness perceptions, may fail to measure unique characteristics of different illnesses. This 
study modified and validated the IPQ-R for breast cancer survivors, to provide detailed 
understanding of the specific illness perceptions held by these patients.  
Design: Initial modifications were made following qualitative interviews and were revised in 
a think-aloud study. The modified scale was tested in 753 breast cancer survivors prescribed 
tamoxifen.  Modifications included adding a tamoxifen consequences scale and adapting the 
timeline scales to measure beliefs around risk of recurrence and cure. A confirmatory factor 
analysis was conducted on the modified questionnaire and an exploratory factor analysis on 
the causal beliefs scale. Test-retest reliability, internal consistency and construct validity were 
also examined.  
Results: The proposed eight factor structure showed acceptable model fit, with high loadings 
and good reliability for all subscales. Correlations between subscales were consistent with 
theory and previous research.  
Conclusions: The IPQ-BCS is valid and reliable, and provides unique understanding of 
specific perceptions held by this population, including beliefs surrounding risk of recurrence 
and consequences of ongoing hormonal treatment. Identifying these perceptions will aid 
development of interventions targeting depression, fear of recurrence and medication non-
adherence.  
Keywords: illness perceptions, scale validation, confirmatory factor analysis, IPQ-R, breast 
cancer, tamoxifen 
 
Introduction 
Illness representations or perceptions, which form part of the Common Sense Model of Self-
Regulation (CSM; Leventhal, Diefenbach, & Leventhal, 1992), predict a range of outcomes, 
including quality of life (QOL) (Petrie, Jago, & Devcich, 2007), fatigue (Jopson & Moss-
Morris, 2003) and poor physical and mental health (Frostholm et al., 2007; Whittaker, Kemp, 
Page 2 of 30
URL: http://mc.manuscriptcentral.com/ehps-journals E-mail: psychealth@leeds.ac.uk or hpr@fmg.uva.nl   For Peer Review Only
Journal Name   For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2 
 
& House, 2007). The CSM proposes that patients’ coping behaviours, such as adherence, are 
guided by their cognitive and emotional representations of their illness. Cognitive 
representations include common sense beliefs about the illness identity (the symptoms / label 
associated with the illness), the cause(s), consequences, timeline and controllability of the 
illness. Patients also have emotional representations, such as fear, which guide how they 
respond to the illness. Finally, patients have a meta-cognitive perception of the coherence of 
their illness representations (Moss-Morris et al., 2002). The development of the Illness 
Perceptions Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, & Horne, 1996), the Brief 
Illness Perceptions Questionnaire (Brief IPQ; Broadbent, Petrie, Main, & Weinman, 2006) 
and the Revised Illness Perceptions Questionnaire (IPQ-R; Moss-Morris et al., 2002) allowed 
researchers to quantify illness representations and increased empirical research on the role of 
illness perceptions in areas such as coping, medication adherence and health outcomes.   
The IPQ-R has shown good internal reliability and test-retest reliability, as well as sound 
discriminant, known group and predictive validity (Moss-Morris et al., 2002). However, it 
was developed as a generic scale for use across different illness groups and therefore may not 
provide insight into the unique beliefs of different patient groups (French &Weinman, 2008). 
Whilst the authors of the IPQ-R recommend that the scale is modified for use in different 
contexts (Moss-Morris et al., 2002), validated modified versions are currently lacking.  
Researchers often rely on very minor modifications such as adding symptoms or causes 
which may not tap into illness specific beliefs. Think-aloud studies have shown that patients 
can struggle to answer questions on the IPQ. Patients enrolled in physiotherapy or a 
preoperative exercise programme had some difficulty completing the Brief IPQ and 
occasionally misinterpreted questions (van Oort, Schroder, & French, 2011). Another study 
showed that patients with type 2 diabetes had difficulties with the concepts of cure and 
symptoms and misunderstood the negative wording on some questions on the IPQ-R 
(McCorry, Scullion, McMurray, Houghton, & Dempster, 2013).This highlights the need to 
explore the face validity of IPQ-R items in different groups of patients and to test the face 
validity of modifications using think-aloud methods.  
One patient group for whom modifications may be particularly pertinent are breast cancer 
survivors (BCS). There are around three million BCS living in the US and another 200,000 
women are diagnosed with breast cancer every year (American Cancer Society, 2014). These 
patients have completed their active treatment and may no longer consider themselves to be 
ill, although continued therapy and monitoring is required. They may therefore struggle to 
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answer questions on the IPQ-R about current illness or current symptom control. However, 
BCS experience a myriad of psychosocial issues and measuring illness perceptions is relevant 
to understanding these ongoing reactions to their previous cancer. For example, around a 
quarter of BCS experience depression or fatigue, and up to 70% show clinical levels of fear 
of cancer recurrence (FCR) (Cvetković & Nenadović, 2016; Servaes, Gielissen, Verhagen, & 
Bleijenberg, 2007; Thewes et al., 2012). Others also struggle to cope with long term 
hormonal therapy such as tamoxifen, which is prescribed for up to ten years as adjuvant 
treatment for women with oestrogen receptive positive breast cancer (about 75% of all breast 
cancers; Harrell et al., 2007). Whilst tamoxifen is one of the most effective systemic 
treatments available for breast cancer, it can cause unpleasant side effects (Garreau, 
Delamelena, Walts, Karamlou, & Johnson, 2006) and both non-adherence and non-
persistence rates are often as high as 50% within five years of treatment (Hershman et al., 
2010; Kostev, Haas, & Hadji, 2012; Owusu et al., 2008). Non-adherence to tamoxifen is 
associated with significantly increased risk of recurrence and mortality (Barron, Cahir, Sharp, 
& Bennett, 2013; Hershman et al., 2011; Makubate, Donnan, Dewar, Thompson, & 
McCowan, 2013). However, little is known about how illness perceptions and beliefs may 
affect adherence in this population.  
An IPQ modified to address beliefs about a past illness, possibility of recurrence and ongoing 
adjuvant treatment will allow researchers to investigate illness representations alongside BCS 
specific coping (including adherence) and psychological outcomes. The CSM has been 
suggested as a useful framework for understanding FCR (Fardell et al., 2016) and other breast 
cancer survivorship issues (Kaptein et al., 2015). Further, identifying illness perceptions 
idiosyncratic to BCS could aid development of interventions, which have the potential to 
improve psychological wellbeing and QOL (Simard et al., 2013).  
This study aimed to modify the IPQ-R for use with BCS. We focused specifically on women 
taking tamoxifen in order to get a more homogenous sample and to tap into illness beliefs 
specific to adjuvant therapy. Following advice from French and Weinman (2008), we used a 
mixed methods approach to modify and validate the questionnaire.  
The specific objectives were:  
1. To conduct qualitative interviews based on the CSM to elicit key beliefs held by BCS 
taking tamoxifen;  
2. To use these interviews to develop a modified version of the IPQ-R  (the IPQ-BCS);   
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3. To test the face validity of this modified questionnaire using think aloud interviews 
and modify further if indicated; 
4. To assess the factor structure, internal consistency and test-retest reliability of the 
modified IPQ-BCS in a large cross sectional study of BCS;  
5. To assess construct validity of the new subscales using inter-correlations between 
subscales and relationships between subscales and psychological variables (beliefs 
about medications and distress).  
It was hypothesised that IPQ-R subscales would show correlations similar to that found in 
previous research (Hagger & Orbell, 2005; Moss-Morris et al., 2002). We hypothesised that 
distress would be associated with higher consequences, identity, emotional representations 
and risk of recurrence beliefs; that tamoxifen necessity beliefs would correlate with treatment 
control; and that tamoxifen concerns would correlate consequences and identity beliefs.  
 
Method 
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207). 
Qualitative study 
Participants and procedure  
Participants were recruited through an oncology clinic in a London hospital and through 
online advertisements, as part of a larger study investigating women’s experiences of taking 
tamoxifen. Patients were eligible if they were female, over the age of 18 and had been 
prescribed tamoxifen post primary breast cancer. Patients were told about the research by 
their clinician, and if interested they were introduced to a researcher and given an information 
sheet. Women who responded to online advertisements were screened for eligibility and 
given information about the study.  
A follow up call was made two days later to arrange an interview. This was part of a larger 
qualitative study to explore women’s experiences of taking tamoxifen. Patients were 
interviewed face to face or over the telephone. Informed consent was taken prior to each 
interview. Interviews were recorded and transcribed verbatim. Participants were first asked a 
series of general questions about their experience of tamoxifen, before being asked specific 
questions regarding their illness perceptions for modification of the IPQ-R (See Table 1 for 
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interview schedule). Thirty-two women took part in the larger qualitative study, of whom 18 
were asked the additional questions specifically relating to the modification of the 
questionnaire. Data collection for these additional questions ceased once data saturation was 
reached and only these questions were analysed in this study. Thus, data from 18 women 
were analysed.  Participant demographics are shown in Table 2.  
[TABLE 1 NEAR HERE] 
Item development  
Interviews were analysed using deductive analysis. Using the CSM as a framework, themes 
were generated around prevalent beliefs and perceptions. Changes to the questionnaire were 
made to reflect the language used by participants. A key theme was that women did not 
identify as currently having breast cancer. All questions were amended to avoid asking 
women about their breast cancer in the present tense. Original and amended items are shown 
in Supplementary Material.  
A second theme suggested women attributed few symptoms to breast cancer. Therefore the 
identity scale was amended to assess symptoms which were (a) attributed to breast cancer, (b) 
to tamoxifen treatment and (c) to their previous / other treatment. Analysis of the interviews 
elicited specific tamoxifen related symptoms. Ten new symptoms, such as hot flushes and 
change in sex drive were added to the original list of fourteen symptoms in the core version 
of the IPQ-R (See Table 3 for list of additional symptoms).  
When asked about control, consequences and causes women tended to discuss their risk of 
recurrence instead of their breast cancer. Therefore, to effectively assess control beliefs, the 
personal and treatment control subscales were amended so that the word ‘illness’ was 
replaced with ‘risk of recurrence’. The treatment control items were asked specifically in 
relation to tamoxifen. In addition to the existing illness consequences scale, a new scale was 
added to assess the consequences of taking tamoxifen, as this was a dominant theme 
identified in the interviews. With regards to timeline beliefs, the interviews showed that 
women did not have symptoms which come and go. The cyclic timeline scale was removed 
and a new scale was added to assess risk of recurrence. Likewise, the timeline acute / chronic 
scale was amended to assess the extent to which women believe that their breast cancer is 
cured, as the interviews showed that these beliefs were much more pertinent than beliefs 
around the chronic nature of breast cancer itself. The coherence scale was modified to 
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measure understanding of tamoxifen treatment rather than breast cancer. Finally, as women 
discussed fear around risk of recurrence rather than fear around breast cancer, the emotional 
representations scale was amended to reflect this. The cause scale was modified by adding 
breast cancer specific causes such as hormonal influence and removing causes which were 
not applicable. Examples of changes to specific items are shown in Table 3.  
Think-aloud study 
After item modification, a think-aloud study was conducted to examine if items on the new 
IPQ-R were being understood and interpreted in the expected way. Eleven women from the 
interview study were invited to take part in the think aloud study and eight agreed. Think 
aloud studies involve patients verbalising their thought process as they answer the 
questionnaire (Ericsson & Simon, 1998). These methods have been used previously to 
examine questionnaires assessing illness perceptions (van Oort et al., 2011), theory of 
planned behaviour (French, Cooke, McLean, Williams, & Sutton, 2007) and QOL 
(Westerman et al., 2008). Participants were asked to complete the modified IPQ-BCS and to 
verbalise everything they were thinking as they were completing the questionnaire. If they 
were quiet for a long period of time, they were prompted to think aloud as they were 
considering the question. The think-aloud sessions were conducted over the telephone and 
participants consented to be audio recorded. 
[TABLE 2 NEAR HERE] 
The think-aloud interviews showed that women could understand the questionnaire and that 
they found it relevant and applicable. However, several issues were identified which led to 
further modifications. The instructions to both the identity and cause scales were modified to 
improve their clarity. A few participants remarked that some items in the personal and 
treatment control scales were worded too severely and that they were unsure how to answer 
them. Therefore the items were amended to reflect this. Several other items were revised 
slightly to enhance the chance they would be applicable for all participants or to ensure they 
were being correctly interpreted. Some women remarked on the repetitiveness of questions, 
so where possible items were deleted (See Supplementary Material).  
[TABLE 3 NEAR HERE] 
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Quantitative study 
Participants and procedure 
Participants were recruited through oncology clinics at 25 NHS Trusts throughout England 
and through online advertisements. Patients were eligible if they had a diagnosis of primary 
breast cancer and if they had been prescribed tamoxifen. Participants had to be female and 
over the age of 18. Patients were approached by a member of their clinical team during a 
routine clinic appointment or received an invitation in the post from their clinical team. They 
were given information about the study along with the questionnaire and a return envelope. 
After providing informed consent, participants either completed the questionnaire in the 
clinic or took it home to return to the researcher. Participants who were recruited online 
responded to an advert and after being screened for eligibility, were sent information about 
the study along with a link to an online questionnaire. Participants gave informed consent 
whilst completing the online questionnaire. A separate sample was recruited to assess the 
test-retest reliability of the IPQ-R. This sample was recruited from four NHS Trusts. 
Participants were given information about the study from the clinical team and once 
consented, they completed the first questionnaire in clinic. Participants were either posted the 
second questionnaire or given a link to complete it online two weeks later, whichever was 
their preference. Telephone reminders were made if the second questionnaire had not been 
returned within one week.  
Measures  
Modified IPQ-R (IPQ-BCS). Participants completed the modified version of the IPQ-R (IPQ-
BCS), which included subscales measuring identity, cure beliefs, risk of recurrence, 
tamoxifen consequences, breast cancer consequences, personal control over recurrence, 
tamoxifen control, coherence, emotional representations and causes. All questions were 
scored on a five point Likert type scale ranging from Strongly Agree to Strongly Disagree 
with the exception of the identity scale where participants ticked each column to indicate if 
they experienced that symptom. Each subscale included four items, with the exception of 
cure beliefs, tamoxifen consequences and emotional representations, which included five 
items. The identity subscale was calculated by totalling the number of symptoms which were 
attributed to tamoxifen. Symptoms which were added to the original list of symptoms are 
shown in Table 3.  
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Hospital Anxiety and Depression Scale (HADS).The HADS is a 14 item scale measuring 
depression and anxiety (Zigmond & Snaith, 1983). The total distress scale was used in this 
study, as a large meta confirmatory factor analysis has shown evidence of a strong general 
HADS factor rather than two distinct subscales (Norton, Cosco, Doyle, Done, & Sacker, 
2013). Each item is scored on a scale of 0 - 3, with higher scores reflecting higher levels of 
distress. The HADS has shown good reliability in patients with breast cancer (Matthews et 
al., 2014; Stanton, Petrie, & Partridge, 2014).  
Beliefs about Medicines Questionnaire (BMQ).The BMQ-Specific measures beliefs 
surrounding the necessity of taking medications and concerns about adverse effects (Horne, 
Weinman, & Hankins, 1999). The word medication was replaced with the word tamoxifen for 
all items. Each item is rated on a five point Likert type scale. A higher score on each subscale 
indicates stronger necessity or concern beliefs. The scale has been used many times in BCS 
with Cronbach’s alpha values of 0.79 - 0.86 and 0.72 - 0.84 for the necessity and concerns 
scale respectively (Bender et al., 2014; Corter, Findlay, Broom, Porter, & Petrie, 2013; Jacob 
Arriola et al., 2014).  
Statistical analysis  
Missing data was less than 5% and were replaced using mean substitution. A Confirmatory 
Factor Analysis (CFA) was conducted on the modified IPQ-BCS using Mplus version 7 to 
test the hypothesised model of eight subscales (cure beliefs, tamoxifen consequences, risk of 
recurrence, breast cancer consequences, personal control, treatment control, coherence and 
emotional representations). CFA is the gold standard method for evaluation of construct 
validity in psychometric tests (Hu & Bentler, 1999). The CFA was conducted using weighted 
least squares with means and variances corrected (WLSMV), as the data was measured on an 
ordinal categorical scale. Multiple indices were used to assess model fit. Chi-squared was not 
used as it is sensitive to sample size (Byrne, 2001). The Comparative Fit Index (CFI), Root 
Mean Square Error of Approximation (RMSEA) and Tucker Lewis Index (TLI) were used. 
CFI or TLI values of greater than 0.95 suggest acceptable model fit (Hu & Bentler, 1999). 
RMSEA values of 0.08 indicate reasonable fit and values of under 0.06 indicate good fit (Hu 
& Bentler, 1999). The reliability of each subscale was tested using Cronbach’s alpha. Test-
retest reliability was assessed using intra-class correlation of each subscale at baseline and 
two week follow up. Discriminant validity was assessed using inter-correlations between 
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IPQ-R dimensions. Construct validity was assessed by examining the correlations between 
IPQ-R dimensions and additional variables (beliefs about medications and distress).   
It is recommended that the causal attribution scale be examined in an exploratory fashion 
(Dempster & McCorry, 2012); therefore Exploratory Factor Analysis (EFA) was used as it 
does not specify an underlying factor structure. Item frequencies were visually inspected and 
items were removed if the majority of participants did not see them as a cause. An EFA was 
then conducted using the SPSS R-menu for ordinal factor analysis based on polychoric 
correlations (Basto & Pereira, 2012). The number of factors to retain was assessed using 
parallel analysis (Horn, 1965). The factor analysis was conducted using Maximum 
Likelihood extraction and Geomin Q-Q rotation.  
Results  
Data was collected from 753 participants. Participants were all female and had been 
diagnosed with Stage I – III breast cancer (Table 2). Mean age was 53 (SD=10.5) and 
participants were on average 33 months post breast cancer diagnosis (SD=24, range 2 months 
– 16 years).   
Confirmatory Factor Analysis   
The sample size exceeded the requirements of at least 3 cases per item (Tabachnick & Fidell, 
2007). Visual inspection of the data showed the items generally correlated as expected within 
the eight subscales, indicating that a CFA was appropriate. The 35 item IPQ-BCS showed 
acceptable model fit (RMSEA = 0.08, 95% CI= 0.08 – 0.09, CFI = 0.95, TLI = 0.94). In 
order to reduce the length of the scale, one item (with the lowest factor loading) was removed 
from each of the three subscales with five items (tamoxifen consequences, cure beliefs and 
emotional representations). Removing these items did not change the overall model fit, and 
therefore this briefer questionnaire is preferred where all subscales have four items. Table 4 
shows the factor loadings for each of the items under each of the subscales. Factor loadings 
were all well above the required threshold of 0.40 (Ford, MacCallum, & Tait, 1986), ranging 
from 0.63 to 0.95. 
[TABLE 4 NEAR HERE] 
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Internal and test-retest reliability  
All scales showed excellent reliability, with Cronbach’s alpha values ranging from .76 to .92 
(Table 4). Test-retest reliability was tested in a separate sample of 48 women. Participants 
completed the questionnaire twice; on average 18 days apart (range 11 – 31). The intraclass 
correlation coefficients for each scale ranged from 0.77 to 0.94 indicating excellent test-retest 
reliability (Table 4).  
Exploratory Factor Analysis on cause items  
Item frequencies and correlations were explored visually and two items were removed from 
the EFA. Item 3 (A germ or virus) was removed as it did not correlate with other items and 
only 5% of participants agreed that it might be a risk factor for recurrence. Item 12 (smoking) 
was also removed, as only 24% of participants provided data for this question. Hormonal 
influence was the strongest item, with 81% of participants agreeing that it was a risk factor.  
Parallel analysis was used on eleven causal items to assess the number of factors to retain, 
and indicated a three factor solution, explaining 46% of the total variance. Factor loadings are 
shown in Table 5. The first factor, labelled psychological attributions, included items relating 
to stress, worries and emotional state. The second factor, labelled health behaviours, included 
items such as diet and eating habits, and exercise. These two factors showed good reliability 
(.85 and .72 respectively). The final factor included item 11 (ageing) and item 13 (hormonal 
influence). However, hormonal influence had a factor loading of below .4 and the reliability 
of the factor was very low (.44). Therefore, these items might be best considered individually 
and not as part of a sub-scale. Item 2 (runs in the family) and item 5 (chance or bad luck) did 
not load onto any factors. 
[TABLE 5 NEAR HERE] 
Examination of the Identity scale  
Each symptom was experienced by at least 13% of participants. Over 40% of participants had 
experienced pain, weight loss/gain, hot flushes, night sweats, fatigue, sleep difficulties, joint 
pain and loss of sex drive. Patients experienced on average 7.8 symptoms (SD = 5.9). 
Symptoms were more commonly attributed to tamoxifen (mean = 5.8, SD = 4.9), than to 
breast cancer (mean=2.1, SD = 3.2) or previous/other treatment (mean = 2.0, SD = 3.6).  As 
symptoms were rarely attributed to breast cancer, identity was represented by the total 
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number of symptoms attributed to tamoxifen. All symptoms were most commonly attributed 
to tamoxifen, with the exception of pain which was attributed to breast cancer by 29% of 
participants and to tamoxifen by 14% of participants. Hot flushes were the most common 
symptom attributed to tamoxifen (65%), followed by night sweats (55%), weight loss / gain 
(41%), joint pain (37%), fatigue (35%), leg cramps (35%) and vaginal dryness, itchiness or 
discomfort (35%). These results provide support for the validity of the symptoms included in 
the scale as well as the different sources of attribution.  
Construct validity  
Inter-correlations between the IPQ-BCS subscales are shown in Table 6. The direction and 
size of the correlations are consistent with previous research (Hagger & Orbell, 2005; Moss-
Morris et al., 2002), and with what would be expected due to the underlying theory. 
Tamoxifen consequences and breast cancer consequences were positively correlated. Both 
consequences scales correlated positively with emotional representations and risk of 
recurrence and negatively with cure beliefs, treatment control. Cure beliefs had a moderate 
negative correlation with risk of recurrence. Personal control and treatment control were 
strongly correlated. Both control scales correlated positively with coherence and cure beliefs 
and negatively with risk of recurrence. Emotional representations was negatively correlated 
with cure beliefs, treatment control and positively correlated with risk of recurrence. Identity 
beliefs correlated positively with tamoxifen consequences, risk of recurrence, breast cancer 
consequences and emotional representations.  
[TABLE 6 NEAR HERE] 
To further explore the validity of the constructs of the IPQ-BCS subscales, correlations were 
examined with distress using the HADS and treatment beliefs using the BMQ. These 
correlations were consistent with hypothesised relationships and supported the construct 
validity of the IPQ-R dimensions (Table 7). HADs distress correlated positively with identity, 
consequences, risk of recurrence and emotional representations, and negatively with cure 
beliefs and treatment control. BMQ Tamoxifen concerns correlated positively with IPQ-BCS 
tamoxifen consequences, breast cancer consequences, identity and emotional representations, 
and negatively with treatment control and coherence. BMQ Tamoxifen necessity beliefs 
correlated positively with IPQ-BCS emotional representations and treatment control.  
[TABLE 7 NEAR HERE] 
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Discussion  
This paper developed and validated a modified version of the IPQ-R for use with BCS 
prescribed tamoxifen. The modified version includes an identity scale which has been 
modified to assess symptoms attributed to tamoxifen, the original illness consequences scale 
and a new tamoxifen consequences scale. The timeline acute scale was amended to measure 
cure beliefs and the timeline cyclical was replaced with a risk of recurrence scale.  The 
personal control, treatment control and emotional representations scales were amended to 
assess risk of recurrence rather than current cancer. The coherence scale was amended to 
measure coherence around tamoxifen rather than breast cancer. The 35 item IPQ-BCS 
showed acceptable model fit, with high factor loadings on the conceptual subscales, and high 
reliability for all subscales. To decrease participant burden, this was reduced down to a 32 
item questionnaire where each subscale has four items. This modification did not affect 
model fit and the reliability for each scale remained high, demonstrating that the removed 
items were redundant and that the shortened questionnaire is sufficient to understand these 
constructs. This modification and validation of the IPQ-R for use in BCS was a vital step in 
furthering understanding of illness perceptions held by BCS. The qualitative interviews we 
conducted showed that women would have had difficulty answering questions on the original 
IPQ-R regarding their current illness and breast cancer symptoms. The think-aloud study 
showed that items on the modified IPQ-BCS were easy to interpret and to answer.  
These results provide support for the CSM and the idea that BCS hold perceptions about their 
previous breast cancer and ongoing treatment and survivorship. Investigating these illness 
perceptions will enhance understanding of the psychosocial issues associated with breast 
cancer survivorship and will help with developing interventions to reduce distress or improve 
QOL in this population. The modified IPQ-BCS assesses beliefs which would not have been 
assessed with the original IPQ-R, such as beliefs around risk of recurrence and cure. These 
beliefs are likely to be relevant to understanding FCR and depression in BCS. The benefit of 
using the IPQ-BCS to assess FCR is that it allows examination of both perceptions of risk 
(risk of recurrence scale) and emotional responses to this risk perception (emotional 
representations scale). Whilst they are correlated, perceptions of the likelihood of a 
recurrence differ from the emotions (e.g. fear, distress) that women feel in response to this 
risk perception. Understanding these separate constructs and how they relate to distress or 
QOL will aid development of interventions to reduce FCR. Furthermore, the IPQ-BCS allows 
these risk of recurrence beliefs to be measured alongside other illness perceptions, such as 
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control or consequences, which feed into beliefs around risk of recurrence (Fardell et al., 
2016). The IPQ-BCS could be supplemented with a more complex FCR scale which also 
assesses hypervigilant checking behaviours, functional impairment of FCR or FCR in relation 
to actual risk.  
The IPQ-BCS also measures beliefs regarding tamoxifen treatment specifically, rather than 
the more generalised treatment control scale included in the IPQ-R.  The IPQ-BCS assesses 
consequences of ongoing tamoxifen treatment as well as breast cancer consequences, and 
measures treatment control specifically with regards to tamoxifen treatment. This scale could 
therefore be used to identify illness and treatment beliefs related to non-adherence in this 
population. Previous studies have found problems with the treatment control subscale of the 
IPQ-R, such as low reliability and cross-loading of items (Brzoska, Yilmaz-Aslan, 
Sultanoglu, Sultanoglu, & Razum, 2012; Ibrahim, Desa, & Chiew-Tong, 2011; Moss-Morris 
et al., 2002). This is likely due to participants being unsure as to which treatment the 
questions are referring to. Amending this subscale to specifically assess tamoxifen treatment 
may have overcome these issues, as the IPQ-BCS treatment control subscale showed good 
reliability and was free from cross-loading. This scale could also be amended to assess 
treatment control specific to aromatase inhibitors or hormone therapy in general. 
The EFA on the cause scale produced three factors. Factor one (psychological attributions) 
and factor two (health behaviours) showed good reliability. However some items did not load 
onto any factors or had low factor loadings. These results are not consistent with the original 
IPQ-R factor structure (Moss-Morris et al., 2002). However, several papers have found a 
factor structure which is hard to interpret (Nicholls, Hill, & Foster, 2013; Wittkowski, 
Richards, Williams, & Main, 2008). In a sample of Greek cancer patients, Giannousi et al. 
(2010) also found that items 2 (hereditary), 5 (chance or bad luck) and 11 (ageing) did not 
load onto any factors.  Whilst hormonal influence and chance or bad luck did not load onto 
any factors in this analysis, they were the most consistently endorsed causes and therefore 
they should be considered as individual items in future analysis or larger subscales related to  
these constructs should be developed . Whilst attempts were made to amend the cause scale 
to enhance its applicability, further modifications may be needed to develop a more robust 
factor structure. 
Correlations between IPQ-BCS subscales were consistent with theory and previous research 
and showed good construct validity. The original consequences scale correlated positively 
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with the new tamoxifen consequences subscale, but the correlation was only moderate, which 
supports the idea that patients can differentiate symptoms from their breast cancer and their 
tamoxifen treatment. Previous research in a cancer setting has found overlap of the 
consequences and emotional representations scales, where items from both subscales loaded 
onto the same factor (Giannousi et al., 2010). However, the IPQ-BCS correlations between 
these subscales were only moderate and the hypothesised factor structure was supported, 
suggesting that emotional representations around recurrence are distinct from consequences 
of breast cancer. The risk of recurrence scale, which was adapted from the previous timeline 
cyclical scale, showed that having high beliefs of a recurrence was associated with higher 
consequences, higher emotional representations and lower cure beliefs.  
The personal and treatment control subscales were positively correlated, but the correlations 
were low enough to support the assumption of two distinct constructs, which is consistent 
with previous research (Dempster & McCorry, 2012; Giannousi et al., 2010; Moss-Morris et 
al., 2002).  Women who scored highly on the two control subscales were less likely to believe 
they would have a recurrence, more likely to believe their breast cancer had been cured and 
more likely to have higher coherence beliefs. Women who attributed a high number of 
symptoms to tamoxifen were significantly more likely to believe they would have a risk of 
recurrence and less likely to believe they were cured, but these were small correlations. This 
is consistent with correlations found in previous research (Hagger & Orbell, 2003) and 
suggests that there is a relationship between symptom experience and perceptions of risk.    
The correlations between IPQ-BCS subscales, HADS distress and BMQ treatment beliefs 
provided further support for construct validity. Higher concerns about tamoxifen were 
associated with higher tamoxifen consequences, a greater number of symptoms attributed to 
tamoxifen, and to a lesser extent, higher breast cancer consequences. This is expected in this 
population as tamoxifen concerns focus almost exclusively on side effects (Moon, Moss-
Morris, Hunter, & Hughes, 2016) and are therefore related to beliefs around consequences 
and symptom attribution. Understanding the interactions between illness perceptions and 
medication beliefs may help to understand medication non-adherence in BCS (Horne & 
Weinman, 2002). HADS distress was associated with tamoxifen consequences, breast cancer 
consequences and emotional representations. These relationships make theoretical sense, as 
greater illness consequences are likely to contribute to levels of distress. However, as this was 
cross-sectional data, the direction of the effect cannot be established. It may be that women 
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who experience higher levels of distress perceive greater consequences from their illness or 
ongoing treatment.  
Strengths of this study include the large sample size and robust analysis. The scale was 
amended based on interviews with patients, and before being analysed it was subject to think-
aloud analysis. Furthermore, patients were recruited from hospitals throughout England, 
which should enhance the generalisability of the results. However, there were several 
limitations. Firstly, participants from the same sample were used to develop the items on the 
questionnaire and to test the questionnaire in the think aloud studies. Secondly, the factor 
structure has only been tested and validated in one sample. Future research could test whether 
the IPQ-BCS could be modified further for use in different cancer types with similar 
survivorship issues to BCS. Overall, results suggest that the modified IPQ-BCS is a valid and 
reliable measure. It is well understood in BCS and has a clear factor structure with ten 
distinct constructs (cause, identity, cure, tamoxifen consequences, risk of recurrence, breast 
cancer consequences, personal control, treatment control, coherence, emotional 
representations). Utilising this scale will help us to understand how women feel about their 
illness and their ongoing treatment as they move into survivorship.  Illness perceptions have 
been shown to be relevant to many of the psychosocial issues inherent to BCS, such as 
fatigue, non-adherence, distress and FCR. Using the IPQ-BCS will allow researchers to see 
how dimensions such as emotional representations and sense of coherence affect illness 
behaviours such as adherence, or outcomes such as QOL or survival, and will help generate 
interventions to support these patients. Whilst the scale was developed for tamoxifen 
treatment, it is likely it will be equally as applicable for women who have been prescribed 
other hormonal therapy such as aromatase inhibitors. It can also be used in other areas, such 
as to investigate beliefs around cancer in relation to FCR, fatigue or distress.  
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Table 1. Interview schedule for qualitative interviews  
1. Are there any specific side effects that you have experienced?  
- Ones that your doctor did not tell you about? 
2. Do you believe that your previous treatment has cured your breast cancer? 
3. Do you still experience ongoing effects from your previous treatment (chemo, surgery, 
radio)?  
4. Do you still see yourself as having breast cancer?  
- What is your relationship with breast cancer?  
5. What do you see as the main consequences of Tamoxifen? 
6. What do you see as the main consequences of breast cancer? 
7. Do you think that tamoxifen is preventing a risk of recurrence?  
8. What else might be impacting a risk of recurrence?  
9. Is there anything else you can do to control this (prevent risk of recurrence)?  
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Table 2. Demographics characteristics of participants.  
 
Interview study  
n=18 
Think aloud study  
n=8 
Factor analysis  
n=753  
Test-retest 
reliability  
n=48  
Age  mean (SD) 
 53 (10.2)  
Range 36 –  63  
53 (9.2) 
Range 37 – 63   
53 (10.5)  
Range 30 – 91  
56 (10.3) 
Range 38 - 82 
Race   n (%) 
     White British  
      Other  
 
13 (72%) 
5 (28%)  
 
8 (100%)  
0 (0%) 
 
654 (87%) 
99 (13%)  
 
44 (94%) 
3 (6%) 
Age left full time education n (%) 
     16 or under 
     Over 16  
  
 
304 (40%) 
449 (60%) 
 
25 (52%) 
23 (48%) 
Menopausal status at diagnosis  n (%) 
     Pre-menopausal  
     Menopausal  
     Post-menopausal  
     Unsure 
 
4 (22%) 
2 (11%)  
9 (50%) 
3 (17%)  
 
2 (25%) 
1 (12.5%) 
4 (50%) 
1 (12.5%)  
 
414 (55%) 
86 (11%) 
202 (27%) 
33 (4%)  
 
Months since breast cancer diagnosis  
Mean (SD)  
36 (25) 
Range 1 year – 
5.5 years 
25 (19)  
Range 1 year – 6 
years  
33 (24) 
Range 2 months – 
16 years  
45 (25) 
Range 1 month – 
9 years 
Stage at diagnosis n (%) 
     Stage I  
     Stage II  
     Stage III  
  
 
321 (43%) 
339 (45%) 
93 (12%)  
 
Previous treatment   n (%) 
     Lumpectomy  
     Single mastectomy  
     Double mastectomy 
     Chemotherapy  
     Radiotherapy  
 
12 (67%) 
2 (11%) 
1 (5%) 
7 (44%) 
15 (83%) 
 
5 (63%) 
1 (13%) 
2 (25%) 
3 (38%) 
6 (75%) 
483 (64%) 
249 (33%) 
44 (6%) 
384 (51%) 
557 (74%)  
 
Note. SD, Standard deviation. Blank spaces indicate incidences where data was not collected.  
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Table 3. Examples of changes made to the original IPQ-R.  
 Previous item New item  
Identity scale   Change in libido, hot flushes, leg 
cramps, loss of concentration, night 
sweats, joint pain, vaginal 
dryness/itchiness/discomfort, feeling 
down, changes to periods, feeling 
lightheaded 
Timeline acute / chronic 
(cure) 
My illness will last for a long time My breast cancer is cured  
Breast cancer consequences My illness has major consequences 
on my life 
My breast cancer still has major 
consequences on my life 
Tamoxifen consequences -  I can’t function normally whilst taking 
tamoxifen 
Personal control My actions will have no effect on 
the outcome of my illness 
My actions will have no effect on the 
risk of cancer coming back 
Treatment control Tamoxifen treatment can control 
my illness 
Tamoxifen treatment can control my risk 
of recurrence 
Coherence My breast cancer is a mystery to 
me 
Tamoxifen is a mystery to me 
Timeline cyclical (risk of 
recurrence)  
I go through cycles in which my 
breast cancer gets better and worse 
There is a good chance my cancer will 
come back 
Emotional representations I get depressed when I think about 
my breast cancer 
I get depressed when I think about my 
risk of recurrence 
Causes   Hormonal influence, exercise 
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Table 4. Confirmatory Factor Analysis of the 8 factor IPQ-R.  
 1 2 3 4 5 6 7 8 
Symptoms 
attributed 
to 
tamoxifen 
Causes 
Cure            
My treatment has been effective in curing my breast cancer 0.74          
I no longer have breast cancer  0.89          
My breast cancer is cured  0.85          
I still see myself as having cancer  0.81          
Breast cancer consequences            
My breast cancer still has major consequences on my life  0.87         
My breast cancer currently does not have much effect on my life   0.66         
I still experience long lasting effects from my original treatment for breast cancer    0.69         
My breast cancer currently causes difficulties for those who are close to me (e.g. 
emotional difficulties)  
 0.75         
Tamoxifen consequences            
Tamoxifen has major consequences on my life    0.63        
I can’t function normally whilst taking tamoxifen    0.89        
Taking tamoxifen has had an impact on those around me   0.88        
My work / social life has been affected by taking tamoxifen   0.95        
Risk of recurrence            
There’s a good chance my cancer will come back     0.91       
I expect to have a recurrence of cancer in the future      0.95       
I am extremely likely to have a recurrence    0.92       
The chance of my cancer coming back is low     0.72       
Personal control            
There are things I can do to stop the cancer coming back     0.79      
What I do has an influence on whether my cancer comes back      0.77      
There is nothing I can do to help my risk of recurrence     0.87      
My actions will have no effect on the risk of cancer coming back      0.81      
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Treatment control            
Tamoxifen treatment can reduce my risk of recurrence      0.82     
There is very little that can be done to  stop the cancer coming back      0.84     
 Taking tamoxifen will help stop the cancer coming back      0.78     
There is nothing that can help my risk of recurrence       0.82     
Coherence            
Tamoxifen  is a mystery to me       0.76    
I understand how tamoxifen helps prevent cancer recurrence        0.80    
I don’t understand how much tamoxifen can help me       0.83    
I have a good understanding of why I am taking tamoxifen       0.82    
Emotional representations            
I get depressed when I think about my risk of recurrence        0.91   
I worry about my risk of recurrence        0.90   
When I think about the cancer coming back I get upset        0.90   
My risk of recurrence makes me feel afraid        0.94   
Cronbach’s alpha 0.81 0.79 0.87 0.90 0.81 0.76 0.81 0.92   
Test retest reliability (intraclass correlation coefficient)  0.92 0.92 0.92 0.87 0.77 0.91 0.91 0.94 0.86 0.87 
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Table 5. Exploratory factor analysis on the causal items.  
  
Factor 1: 
Psychological 
attributions 
Factor 2: 
Health 
behavio
urs 
Factor 3: 
External 
causes  
Stress or worry  .771 .066 -.040 
Family problems  .907 -.004  -.014 
My own emotional state  .818 -.009  .096 
Diet or eating habits  -.004 .840 -.146 
My own behaviour  .097  .622 .064 
Exercise -.008  .686 .059 
Pollution in the environment  .212 .400 .044 
Ageing .043 .004 .788 
Hormonal influence  -.097 .209  .330 
Runs in the family  .076 .076  .112 
Chance or bad luck  .002 .067 .239  
Cronbach alpha 0.85 0.71 0.44 
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Table 6. Correlations between IPQ-R subscales.  
 
1 2 3 4 5 6 7 8 
9 
1. Cure  1         
2. Tamoxifen 
consequences 
-.14** 1        
3. Risk of recurrence -.45
**
 .23
**
 1       
4. Breast cancer 
consequences  
-.31
**
 .49
**
 .42
**
 1      
5. Personal control  .15
**
 -.08
*
 -.24
**
 -.13
**
 1     
6. Treatment control  .23
**
 -.17
**
 -.35
**
 -.22
**
 .58
**
 1    
7. Coherence .10** -.10** -.15** -.16** .26** .44** 1   
8. Emotional 
representations 
-.24** .30** .41** .54** -.15** -.20** -.16** 1  
9. Symptoms attributed to 
tamoxifen  
-.12** .56** .19** .36** .04 .00 .05 
.25*
* 
1 
 **p <0.01, *p<0.05  
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Table 7. Correlations between IPQ-R subscales, HADS distress and BMQ necessity and concerns. 
  Distress Concerns 
Necessity 
beliefs 
Cure  -.20
**
 -.18
**
 -.04 
Tamoxifen consequences .53
**
 .56
**
 .10
*
 
Risk of recurrence  .31** .19** .12** 
Breast cancer consequences .55
**
 .40
**
 .15
**
 
Personal control  -.15** -.08* .02 
Treatment control  -.21
**
 -.23
**
 .15
**
 
Coherence -.15** -.28** .07 
Emotional representations  .45
**
 .36
**
 .23
**
 
Symptoms attributed to tamoxifen  .35** .43** .09* 
**p <0.001 
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